secwatch.observer — SEC 8-K summary
======================================

Issuer:     LABCORP HOLDINGS INC. (LH)
CIK:        0000920148
Form:       8-K
Filed at:   2023-10-26T23:59:59+00:00
Accession:  0000920148-23-000078
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Labcorp Q3 revenue up 6.6% to $3.06B; adjusted EPS $3.38 vs $4.01 YoY; narrows full-year guidance
--------------------------------------------------------------------------------

- Q3 revenue $3.06B (+6.6% YoY); Base Business revenue grew 14.0% YoY, partially offset by lower COVID-19 testing.
- GAAP diluted EPS $2.11 vs $3.06 YoY; adjusted EPS $3.38 vs $4.01 YoY.
- Updated FY2023 guidance: adjusted EPS $13.25-$13.75 (midpoint unchanged), FCF $0.85-$0.95B excluding spin items.
- Signed multiple hospital lab agreements including Tufts Medicine, Providence Health, Legacy Health, and Baystate Health.
- Launched ATN Profile, a blood-based test combining three biomarkers to aid Alzheimer's diagnosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/920148/000092014823000078/0000920148-23-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/920148/000092014823000078/lh-20231026.htm
  HTML page:      https://secwatch.observer/filing/0000920148-23-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer